Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
Laufzeit: 01.01.2022 - 31.12.2029
imported
Kurzfassung
EBV-positive nasopharyngeal carcinoma in children and adults